Literature DB >> 21851535

Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer.

Martin Andreas Røder1, Ib Jarle Christensen, Kasper D Berg, Lisa Gruschy, Klaus Brasso, Peter Iversen.   

Abstract

OBJECTIVE: • To investigate serum testosterone levels as a predictor for biochemical failure (BF) after radical retropubic prostatectomy (RRP). PATIENTS AND METHODS: • Prospective cohort study with 227 patients and a median follow-up of 7.7 years. • Total serum testosterone was measured at diagnosis. • Primary endpoint: 5-year BF-free survival defined as first PSA > 0.2 ng/mL. • Testosterone was tested as a predictor of BF as a dichotomized and continuous variable.
RESULTS: • Median (range) age was 62 years (45-74), median PSA 9.9 ng/mL (0.4-96), and median testosterone was 14 nmol/L (2.2-40). • BF occurred for 57 patients (26%) within 5 years. • In multivariate analysis with age, PSA, and biopsy Gleason score, testosterone levels >11 nmol/L were an independent predictor for reduced risk of BF (hazard ratio, 0.53; 95% confidence interval, 0.31-0.90; P= 0.02). • When analyzed as a continuous variable, testosterone was not a statistically significant predictor of BF.
CONCLUSION: • Low pretreatment serum testosterone levels correlate with a higher risk of BF, and testosterone may possess biological information about prostate cancer progression potential, which makes it an independent predictor of biochemical failure after RRP.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21851535     DOI: 10.1111/j.1464-410X.2011.10335.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

1.  Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.

Authors:  Andrea Salonia; Firas Abdollah; Umberto Capitanio; Andrea Gallina; Nazareno Suardi; Alberto Briganti; Giuseppe Zanni; Matteo Ferrari; Fabio Castiglione; Maria Chiara Clementi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2012-03-24       Impact factor: 4.226

Review 2.  Testosterone Therapy Among Prostate Cancer Survivors.

Authors:  Taylor M Nguyen; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-07-27

3.  Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.

Authors:  A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-06       Impact factor: 5.554

Review 4.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

5.  LHRH and LHR genotypes and prostate cancer incidence and survival.

Authors:  Sue Ann Ingles; Stephen V Liu; Jacek Pinski
Journal:  Int J Mol Epidemiol Genet       Date:  2013-11-28

Review 6.  [Testosterone in the management of metastatic prostate cancer].

Authors:  J M Wolff; H P Schmid
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

Review 7.  Androgens, aging, and prostate health.

Authors:  Karin Welén; Jan-Erik Damber
Journal:  Rev Endocr Metab Disord       Date:  2022-06-24       Impact factor: 6.514

8.  Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.

Authors:  Antonio Benito Porcaro; Alberto Bianchi; Giovanni Mazzucato; Sebastian Gallina; Emanuele Serafin; Alessandro Tafuri; Clara Cerrato; Andrea Panunzio; Stefano Vidiri; Damiano D'Aietti; Rossella Orlando; Davide Brusa; Matteo Brunelli; Salvatore Siracusano; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2022-10-05       Impact factor: 2.266

9.  Association of serum calcium with serum sex steroid hormones in men in NHANES III.

Authors:  Mieke Van Hemelrijck; Karl Michaelsson; William G Nelson; Norma Kanarek; Adrian Dobs; Elizabeth A Platz; Sabine Rohrmann
Journal:  Aging Male       Date:  2013-05-14       Impact factor: 5.892

Review 10.  The Role of Testosterone Therapy in the Setting of Prostate Cancer.

Authors:  Katherine M Rodriguez; Alexander W Pastuszak; Mohit Khera
Journal:  Curr Urol Rep       Date:  2018-06-30       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.